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The use of RNA interference (RNAi) to deplete individual proteins from cells or tissue has revolutionised
our ability to characterise gene function. The placenta is an attractive target for studies in which the role
of speciﬁc proteins can be compared with cell culture models and explanted villous tissue where
physiological function can be maintained ex vivo.
In this study, we compared a variety of commercially available reagents and approaches to deﬁne
methods for efﬁcient delivery of siRNA to placental cells. Protocols optimised using ﬂuorescently-labelled
siRNA were subsequently tested using siRNA sequences that target placental alkaline phosphatase
(PLAP), chosen because of its high abundance in trophoblast. mRNA abundance was assayed using qRT-
PCR, and the effect on protein was examined using immunolocalisation.
We report that different protocols are required for BeWo choriocarcinoma cells (nucleofection), primary
cytotrophoblast cells (lipid-based transfection) and villous tissue explants (nucleofection). The results
provide guidelines for optimal siRNA-mediated knockdown in these three models of the human placenta.
 2008 Elsevier Ltd. Open access under CC BY license.1. Introduction
Deletion and mutation have beenwidely used to examine single
gene function in mouse, where more than 100 genes that are
required for placental development have been identiﬁed [1].
However, to date, only a small fraction of these has been shown to
be important for human placental development or function. It is of
interest to develop methods capable of effectively blocking speciﬁc
gene products in the human placenta, both for basic investigations
of gene function and future therapeutic approaches to pregnancy
pathologies such as abnormal fetal growth. The use of inhibitors
can be problematic as availability is limited and many are non-
speciﬁc and have multiple cellular targets. Targeted reduction of
mRNA by RNA interference (RNAi) offers an attractive alternative
approach to reducing the abundance of the corresponding protein
in order to examine function in living cells.
RNA interference by short interfering strands (siRNA) is a normal
post-translational regulatorymechanism and avital part of the innate
immune response, acting as a defense mechanism against viruses by
inhibiting gene expression at the stage of translation [2]. RNAi can be
artiﬁcially induced inmammaliancellsby introducingsynthetic siRNA
(21–23 base pairs in length) or plasmid or viral vectors expressing
short hairpin RNAs (shRNAs) [3]. Many different methodologies,.uk (M. Westwood).
Y license.including lipid-based transfection, retroviruses and electroporation
have been used for in vitro delivery of siRNA into cells and tissue [4],
however the efﬁciency of delivery varies amongst cell types and
optimisation of conditions can be expensive and time-consuming.
In this study we have used non-targeted ﬂuorescently-labelled
siRNA sequences as an initial approach to assay efﬁciency ofmethods
for transfecting BeWo choriocarcinoma cells, isolated primary cyto-
trophoblast cells and placental villous explants. We have shown that
in each system, the method identiﬁed as most efﬁcient produces
signiﬁcant mRNA and protein knockdown using as an exemplar
siRNAdirected against humanplacental alkalinephosphatase (PLAP).
2. Methods
2.1. Determining transfection efﬁciency
Fluorescently-labelled non-targeting siRNA (siGLO red; 50–100nM; Dharmacon,
UK) was used to assess the efﬁciency of a variety of methods for introducing siRNA
into cells and tissue. Following transfection, samples were incubated for 24–48 h
and then cells were ﬁxed in 4% paraformaldehyde for 30 min and tissue embedded
in OCT, snap frozen and sectioned (10 mm). All samples were mounted with Vecta-
shield (Vector Laboratories, UK) containing a nuclear counterstain (DAPI) and
visualised with a Zeiss AxioObserver inverted microscope (Carl Zeiss Inc, Europe).
Transfection was deemed successful when more than 70% of cells contained intra-
cellular ﬂuorescence.
2.2. siRNA sequences
In order to demonstrate that the procedure resulting in themost efﬁcient delivery
of non-targeting siRNA sequences also allowed the depletion of speciﬁc mRNA, cells
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CAGGCTATGTGCTC-30; Dharmacon, UK) designed to target speciﬁcally mRNA encod-
ing the highly abundant placental protein, placental alkaline phosphatase (PLAP;
(GenBank) accession number NM_001632.3) [5]. The sequence was veriﬁed by Basic
Local Alignment Search Tool (BLAST). The effect of targeted (PLAP) siRNA sequences
was compared with 100 nM non-targeting Silencer negative control siRNA (Ambion,
USA) and AllStars negative control siRNA (Qiagen, UK).
2.3. Analysis of PLAP mRNA expression
Total RNA was extracted from placental tissue and from cells using an Absolutely
RNAminiprep ormicroprep kit (Stratagene,USA) respectively, quantiﬁed using aQuant-
iT Ribogreen kit (Molecular Probes) and 100 ng of total RNA from each sample was
reverse transcribed using AfﬁnityScript cDNA synthesis kit (Stratagene, USA). PLAP and
b actin mRNA expression were quantiﬁed by QPCR using a Stratagene MX3000P real
time PCR machine and Stratagene Brilliant SYBR Green I QPCR mastermix, with
5-carboxy-x-rhodamine as a passive reference dye. PLAP was ampliﬁed using 300 nM
primers (Invitrogen UK) designed by Sequence Manipulation Suite SoftwareA
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Fig. 1. Delivery of siRNA to BeWo cells. 24 h after transfection cells were ﬁxed and stained w
using an Amaxa Nucleofector with cell line solution L and program X005 (B). (C) Cells expo
non-targeting (100 nM) or PLAP-speciﬁc siRNA (100 nM) were cultured for 72 h and then ana
using the Kruskal–Wallis test (*p< 0.05 versus control cells) and are presented as media
corresponding experiment. Expression of PLAP protein (green) was analysed 72 h after tran
(red).(http://bioinformatics.org/sms2/pcr_primer_stats.html) and conﬁrmed as speciﬁc by
BLAST analysis: (forward: 50 GCTCATACTCCATGCCCA 30 , reverse: 50 AGACACCCCCA
TCCCATC 30). Primers for b actin mRNA (200 nM; MWG Biotech (UK)) were: forward:
50-AGCCACCCCACTTCTCTCTAA-30 , reverse: 50-ACACGAAAGCAATGCTATCACCT-30 [6].
PLAP and b actin mRNA were quantiﬁed against standard curves generated from total
human placental RNA and human reference total RNA (Stratagene, La Jolla, USA)
respectively. Data were analysed by using the Kruskal–Wallis test and are presented as
median and range mRNA expression relative to the control (untransfected) sample for
the corresponding experiment.2.4. Analysis of PLAP protein expression
Following treatment with siRNA, placental tissue was embedded in OCT, snap
frozen and sectioned (10 mM). BeWo cells and primary cytotrophoblast cells were
ﬁxed in ice-cold methanol. Expression of PLAP protein was assessed by incubating
tissue or cells with mouse monoclonal anti-PLAP antibody (1:500; Sigma clone 8B6)
for 1 h and then FITC-labelled rabbit anti-mouse IgG (46 mg/ml; DakoCytomation)Nucleofector L X005 siGLO
DAPI
PLAP siRNA
PLAP
PI
on-targeting PLAP siRNA
*
ith DAPI (blue) (A); optimal delivery of ﬂuorescently-labelled siRNA (red) was achieved
sed to transfection conditions in the absence of siRNA (mock) or cells transfected with
lysed for PLAP mRNA expression (median and range, n¼ 7). Raw data were analysed by
n and range mRNA expression relative to the control (untransfected) sample for the
sfection with non-targeting (D) or PLAP-speciﬁc siRNA (E); nuclei are stained with PI
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using a Zeiss AxioObserver Inverted Microscope.2.5. Establishing optimal siRNA delivery methods
2.5.1. BeWo cells
BeWo choriocarcinoma cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/Ham’s F12 (F12) (1:1, v/v) containing 10% fetal calf serum and
antibiotics, as previously described [7]. In order to test lipid-based transfection
reagents, BeWo cells were plated on coverslips in 24-well plates and, when
approximately 40–50% conﬂuent, transfected with either Lipofectamine 2000, Oli-
gofectamine (Invitrogen, UK), or Fugene HD (Roche Diagnostics, UK) transfection
reagents in accordance with the manufacturer’s guidelines. Cells destined for
transfection using an electroporation-based system - nucleofection, were grown in
T75 ﬂasks until 70–80% conﬂuent, then trypsinised and counted. 1106 cells/
condition were resuspended in cell line solution L or cell line solution V and
transfected following the manufacturers’ instructions using programs A-020, T-020,
X-001 and X-005 (Amaxa Biosystems, Germany). Following transfection, cells were
plated at approximately 7104/well for 24-well plates and approximately 3105/
well for 6 well plates.
2.5.2. Primary cytotrophoblast cells
Term placentae (38–40 weeks gestation) were collected with written informed
consent and in accordance with Local Ethics Committee approval following
Caesarean section or vaginal delivery from uncomplicated singleton pregnancies.
Cytotrophoblast cells were isolated and maintained in primary culture for up to 90 h
as described previously [8,9].
In order to test lipid-based transfection reagents, cytotrophoblast cells were
plated onto 12 well plates at approximately 2106/well and after 18 h in
culture, transfected using either Lipofectamine LTX (Invitrogen, UK) or Dhar-
maFECT2 (Dharmacon, UK) reagents in accordance with the manufacturers’
guidelines.
Cells intended for transfection by nucleofection were centrifuged at 1000 g for
5 min immediately after isolation and then resuspended in the nucleofection
buffer (100 ml/2106 cells) provided in the basic primary mammalian epithelial
cell nucleofector kit (Amaxa Biosystems, Germany). 2106 cells/condition
were transfected using programme Nucleofector programmes S-005, T-020, T-023Table 1
Summary of cell/tissue characteristics following introduction of siGLO/siRNA sequences
Cell type Analysis No Reagent L
BeWo Transfection efﬁciency
(% cells containing siGLO)
0% L
O
F
Cell Survival (%) 85% L
O
F
PLAP mRNA (%) N/A N
PLAP protein (%) N/A N
Primary trophoblast Transfection efﬁciency
(% cells containing siGLO)
50% L
D
Cell Survival (%) 85% L
D
PLAP mRNA (%) N/A D
PLAP protein (%) N/A >
1st Trimester placental
tissue
Transfection efﬁciency
(% cells containing siGLO)
100% syncytium
0% cytotrophoblast
0% stromal cells
L
a
t
e
0
Cell Survival (%) >90% N
PLAP mRNA (%) N/A N
PLAP protein (%) <20% Nor U-017 and then plated onto 12 well plates at 1–2106 cells/well in 1.5 ml
culture medium (DMEM/Ham’s F12 (1:1, v/v) containing 10% fetal calf serum and
antibiotics).
2.5.3. 1st trimester human placenta explants
First trimester (8–12 weeks gestation) placentae were obtained with written
informed consent and in accordance with Local Ethics Committee approval,
following elective surgical or medical termination of pregnancy. Fresh villous
tissue was dissected under sterile conditions in serum-free DMEM/F12 and small
(approximately 5 mm) pieces were transfected and then transferred to 1%
agarose-coated 24-well tissue culture plates for up to 4 days in 20% O2 at 37 C.
Our previous studies suggest that tissue maintained under these conditions
displays similar morphology and functional characteristics to ﬁrst trimester tissue
cultured at lower oxygen concentrations [10], however researchers wishing to
perform experiments at 20% oxygen should consider the possibility that oxygen
tension may impact on the efﬁciency of siRNA-mediated knockdown of mRNA/
protein.
Lipofectamine 2000, Oligofectamine, Fugene HD, and DharmaFECT2 were
tested, each in accordance with the manufacturer’s instructions, as lipid-based
methods for introducing siRNA sequences into placental explants. In order to
carry out transfection by nucleofection, 2–3 pieces of placental tissue were
placed in 100 ml basic primary epithelial cell nucleofector buffer containing
siRNA or vehicle. Using a wide-ended 1.5 ml Pasteur pipette, tissue and buffer
were transferred to a Nucleofector cuvette and then exposed to programs X005,
X001, U006, U007 and U017 before removal using pipettes supplied with the
Nucleofector kit.3. Results
3.1. BeWo cells
Relatively low percentages of ﬂuorescent cells were observed
after BeWo cells were transfected using Oligofectamine (approx
40%) or Fugene HD (<40%). Approximately 50% of cells were
transfected when Lipofectamine 2000 was used to deliver siRNA,via a number of different methods.
ipid-Based transfection Nucleofection
Cell Line Solution L Cell Line Solution V
ipofectamine 2000: 50%
ligofectamine: 40%
ugene HD: <40%
Prog A020: 60%
Prog T020: 50%
Prog X001: >70%
Prog X005: >90%
Prog A020: 60%
Prog T020: 50%
Prog X001: >70%
Prog X005: >70%
ipofectamine 2000: 40%
ligofectamine: 70%
ugene HD: 70%
Prog A020: 50%
Prog T020: 50%
Prog X001: 60%
Prog X005: >70%
Prog A020: 50%
Prog T020: 50%
Prog X001: 60%
Prog X005: 60%
/A Prog X005: 75% N/A
/A Prog X005: >70% N/A
Basic Mammalian Epithelial Cell Solution
ipofectamine LTX: 80%
harmaFECT2: 95%
Prog S005: Most of surviving cells
Prog T020: Most of surviving cells
Prog T023: Most of surviving cells
Prog U017: Most of surviving cells
ipofectamine LTX: 40%
harmaFECT2: 85%
Prog S005: <30%
Prog T020: <30%
Prog T023: <30%
Prog U017: <30%
harmaFECT2: 60% N/A
70% N/A
ipofectamine 2000, Oligofect-
mine, Fugene HD all gave similar
ransfection
fﬁciencies:100% syncytium;
% cytotrophoblast; 0% stromal cells
Prog X005: 100% syncytium;
70% cytotrophoblast; 30% stromal cells
Prog X001: 100% syncytium;
50% cytotrophoblast; <10% stromal cells
Prog U017: 100% syncytium;
50% cytotrophoblast; 10% stromal cells
Prog U007: 100% syncytium;
80% cytotrophoblast; 40% stromal cells
/A Prog U007: >70%
/A Prog U007: 85%
/A Prog U007: >60%
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Optimal transfection (>90% ﬂuorescent-positive cells in conjunc-
tion with good cell viability) was achieved with the Amaxa
Nucleofector using cell line solution L and program X005 (Fig. 1A
and B; Table 1).
In order to conﬁrm that this methodology gave knockdown of
target proteins, BeWo cells were transfected with non-targeting or
PLAP-speciﬁc siRNA. PLAP mRNA expression was reduced by 75%
after 72 h (p< 0.05; Fig. 1C; Table 1) and immunohistochemical
analysis demonstrated a corresponding reduction in PLAP protein
expression in both cytoplasmic and cell surface-associated pools
(Fig. 1D and E; Table 1). The level of b actin mRNA in BeWo cells was
not affected by transfection with PLAP-speciﬁc siRNA (data not
shown).A
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Fig. 2. Delivery of siRNA to primary term cytotrophoblast cells. 18 h after isolation, primary
48 h later, cells were ﬁxed and stained with DAPI (blue). Images show distribution of siRN
(DharmaFECT2) cells or cells transfected with non-targeting (100 nM) or PLAP-speciﬁc siRNA
Raw data were analysed by using the Kruskal–Wallis test (*p< 0.05 versus control cells
(untransfected) sample for the corresponding experiment. Expression of PLAP protein (gree
(E); nuclei are stained with PI (red).3.2. Primary term cytotrophoblast cells
The nucleofector was unsuitable for transfecting primary
cytotrophoblast cells since this method resulted in high levels
of cell death and only a few of the surviving cells were ﬂuo-
rescently-labelled (Table 1). High levels of intracellular ﬂuo-
rescence (approximately 80% positive cells) were observed
following transfection with Lipofectamine LTX, however there
was some evidence (nuclear fragmentation) of increased
apoptosis (Table 1). Approximately 95% of cells were ﬂuores-
cence-positive when DharmaFECT2 was used to deliver siRNA
(Fig. 2A and B; Table 1). Transfection with DharmaFECT2 was
selected as the optimal method for delivering siRNA sequences
to cytotrophoblast cells. PLAP mRNA expression was notPLAP
PI
DharmaFECT2 siGLO
DAPI
Non-targeting PLAP siRNA
*
PLAP siRNA
cytotrophoblast cells were transfected with ﬂuorescent-labelled siRNA (red) and then
A in control cells (A) or cells transfected with DharmaFECT2 (B). (C) Mock-transfected
(100 nM) were cultured for 48 h and then analysed for PLAP mRNA expression (n¼ 5).
) and are presented as median and range mRNA expression relative to the control
n) was analysed 48 h after transfection with non-targeting (D) or PLAP-speciﬁc siRNA
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levels were reduced by approximately 60% 48 h after delivery
of PLAP-speciﬁc siRNA (p< 0.05; Fig. 2C; Table 1). Similarly,
delivery of PLAP siRNA with DharmaFECT2 resulted in reduced
PLAP protein expression as demonstrated by immunocyto-
chemistry (Fig. 2D and E; Table 1). Transfection of cyto-
trophoblast cells with PLAP siRNA did not affect expression of
b actin mRNA (data not shown).
3.3. First trimester placental explants
In control tissue (no transfection reagents) siRNA could gain
access to the syncytial layer of the placenta. However, neither theA
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Fig. 3. Delivery of siRNA to ﬁrst trimester placental explants. 24 h after transfection tissue wa
siRNA (red) in (A) control tissue (no transfection reagents) and (B) following transfection w
Arrows indicate cytotrophoblast cells (CT), syncytium (ST) and stroma. (C) Tissue exposed to
targeting (100 nM) or PLAP-speciﬁc siRNA (100 nM) was cultured for 72 h and then analysed
test (*p< 0.05 versus control cells) and are presented as median and range mRNA express
Expression of PLAP protein (green) was analysed 48 h after transfection with non-targetingunderlying cytotrophoblast cells nor villous stromal cells were
positive for ﬂuorescently-labelled siRNA (Fig. 3A; Table 1). When
lipid-based transfection reagents were utilised, the transfected
tissue resembled control tissue, with siRNA present only in the
syncytium. However, when tissue was transfected using the
nucleofector, high levels of siRNA were observed in both cyto-
trophoblast cells and in the villous stroma (basic mammalian
epithelial cell solution, programU007; Fig. 3B; Table 1). Preliminary
experiments investigated if nucleofection could also be used to
transfect cytotrophoblast following removal of syncytium by
limited trypsinisation. However, cell viability was severely
impaired following sequential manipulation and the approach was
discontinued. As transfection of intact tissue by nucleofectorPLAP siRNA
PLAP
PI
CT
ST
stroma
Nucleofector U007
stroma
MVM
ST
CT
n-targeting PLAP siRNA
E
*
s ﬁxed and stained with DAPI (blue). Images show distribution of ﬂuorescently-labelled
ith the Amaxa Nucleofector (basic mammalian epithelial cell solution; program U007).
transfection conditions in the absence of siRNA (mock) or tissue transfected with non-
for PLAP mRNA expression (n¼ 4). Raw data were analysed by using the Kruskal–Wallis
ion relative to the control (untransfected) sample for the corresponding experiment.
(D) or PLAP-speciﬁc siRNA (E); nuclei are stained with PI (red).
K. Forbes et al. / Placenta 30 (2009) 124–129 129resulted in delivery of siRNA sequences to cytotrophoblast cells and
stroma in addition to syncytium, this method was chosen for
further evaluation.
PLAP mRNA expression was signiﬁcantly reduced following
transfectionwith PLAP siRNA (85%,p< 0.05; Fig. 3C; Table 1).Neither
mock nor non-targeting siRNA had any effect on PLAP mRNA levels.
Immunoﬂuorescence revealed that PLAP protein expression (in
microvillous membrane and cytotrophoblast cells, as indicated by
arrows)wasmarkedly reducedbyPLAPsiRNA(Fig. 3DandE;Table1).
The expression of b actin mRNA was not affected by nucleofector-
mediated transfection of placental explants (data not shown).
4. Discussion
Different techniques for introducing siRNA oligonucleotides into
human placental cells and tissue offer varying degrees of success in
terms of transfection efﬁciency.We have optimised delivery of siRNA
sequences into placental cell lines, isolated cells and tissue, and
demonstrated efﬁcient knockdown at both mRNA and protein level
of the highly abundant protein, placental alkaline phosphatase.
Most published studies reporting siRNA or antisense oligonu-
cleotide-mediated knockdown in the human placenta have
focussed on cell lines. Though cell lines offer advantages including
convenience and ease of transfection, reported transfection efﬁ-
ciencies vary, and for studies of normal placental function it is
preferable to study primary trophoblast cells and tissue explants.
We are unaware of previous reports of siRNA delivery into primary
cytotrophoblast cells and there are limited available data in
placental tissue.
Calcium phosphate-assisted transfection is a relatively easy and
inexpensive method for introducing RNA or DNA but is reported to
showvery lowefﬁciency in placental cells [11]. Limited deliverywas
achieved with either poly-L-ornithine or DEAE-dextran (25% and
6.25% respectively [11]). More recently siRNA or plasmid DNA has
been introduced into placental cell lines such as JAR, JEG or BeWo
using Lipofectamine, however many of these studies do not report
transfection efﬁciency [12,13], whilst others report efﬁciencies
varying in the range 50–80% using Lipofectamine [14,15]. In our
hands Lipofectamine can be used to introduce siRNA into BeWo
cells however, the transfection efﬁciency is low and subsequent
analysis revealed little effect on protein level (data not shown).
Numerous reagents have been used to deliver siRNA into
primary cells, which are generally considered to be hard to trans-
fect. Zhang et al. [16] have reported successful use of Lipofectamine
2000 in human placental ﬁbroblasts. However, their procedure
involves a trypsinisation step prior to siRNA delivery which is
unsuitable for primary human cytotrophoblast cells, as once iso-
lated and cultured, these cells are non-proliferative and do not
survive further rounds of trypsinisation. We have found that
DharmaFECT2 transfection reagent applied to 18 h primary human
cytotrophoblast cells in culture is an effective method for intro-
ducing siRNA into primary human cytotrophoblast.
In the absence of delivery agents, siRNA spontaneously enters the
syncytium of ﬁrst trimester villous tissue, but cannot access under-
lying cytotrophoblast cells or the villous stroma. This does enable
knockdown of syncytial proteins, as recently demonstrated by the
reduction of p53 and mdm2 in term placenta [15]. In addition to
syncytium, PLAP is expressed in cytotrophoblast cells and to some
extent in stromal cells; here we found only a small reduction in
protein expression without active delivery of siRNA. The nucleo-
fector-basedmethodwedescribedelivers siRNAtoplacentalexplants
to produce knockdown in cell populations beneath the syncytium.
In this study we have used PLAP to demonstrate that an abun-
dant placental protein can be depleted using each of the optimal
delivery methods described. Other gene products may behave
differently depending on siRNA design and half-life of target mRNA,hence speciﬁc optimisation is recommended before undertaking
functional experiments, including target sequences, siRNA
concentrations and exposure times [17].
In summary, this study highlights the importance of validating
delivery methodologies to obtain optimal conditions when using
siRNA. We have demonstrated that effective delivery to primary
cytotrophoblast cells is by transfection with DharmaFECT, whilst
the optimal conditions for introducing siRNA into BeWo cells and
placental explant tissue (beyond the syncytiotrophoblast) is by
electroporation using a nucleofector. As new technologies emerge,
improved siRNA delivery may be expected. At present however, the
techniques described are suitable for studying the role of individual
genes and their translation products in vitro and will aid in the
analysis of placental development and function. Future possibilities
include the introduction of RNAi into the placenta as a therapeutic
strategy for pregnancy complications and diseases with fetal onset.
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